Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2

Trial Profile

Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 01 Jul 2017 Results of post-hoc analysis assessing efficacy and safety, published in the Lancet Neurology.
    • 23 May 2017 Results of retrospective analysis of utilisation of King's ALS Clinical Staging System and the Milano Torino Staging System in capturing disease progression data from this study presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 18 May 2017 Results published in a MT Pharma America media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top